Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 6/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 1/6 |
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥63.40 |
52 Week High | CN¥88.00 |
52 Week Low | CN¥40.14 |
Beta | 2.32 |
1 Month Change | -10.77% |
3 Month Change | 5.07% |
1 Year Change | -15.47% |
3 Year Change | -40.08% |
5 Year Change | n/a |
Change since IPO | -21.40% |
Recent News & Updates
Recent updates
Shareholder Returns
603392 | CN Biotechs | CN Market | |
---|---|---|---|
7D | -5.8% | -1.6% | -0.4% |
1Y | -15.5% | -24.8% | -14.4% |
Return vs Industry: 603392 exceeded the CN Biotechs industry which returned -24.8% over the past year.
Return vs Market: 603392 underperformed the CN Market which returned -14.4% over the past year.
Price Volatility
603392 volatility | |
---|---|
603392 Average Weekly Movement | 9.6% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 8.8% |
10% most volatile stocks in CN Market | 12.7% |
10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 603392 has not had significant price volatility in the past 3 months.
Volatility Over Time: 603392's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1991 | 3,843 | Zixin Qiu | www.ystwt.com |
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. researches, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides COVID 19, HIV and HTLV, Hepatitis, EV-71, and Tuberculosis diagnostics test kits; Hepatitis C and Syphilis detection reagents; automated immunoassays; ELISA kits and rapid tests for infectious disease diagnostics; chemiluminescence and clinical chemistry reagents; immunodiagnostic reagents; and Hepatitis E and human papillomavirus vaccines.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Fundamentals Summary
603392 fundamental statistics | |
---|---|
Market cap | CN¥80.40b |
Earnings (TTM) | CN¥1.25b |
Revenue (TTM) | CN¥5.51b |
64.4x
P/E Ratio14.6x
P/S RatioIs 603392 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
603392 income statement (TTM) | |
---|---|
Revenue | CN¥5.51b |
Cost of Revenue | CN¥1.00b |
Gross Profit | CN¥4.51b |
Other Expenses | CN¥3.26b |
Earnings | CN¥1.25b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
Earnings per share (EPS) | 0.98 |
Gross Margin | 81.81% |
Net Profit Margin | 22.64% |
Debt/Equity Ratio | 2.2% |
How did 603392 perform over the long term?
See historical performance and comparison